13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
49 檔
62.0%
At the close of Q1 2024, Artia Global Partners LP disclosed equity holdings valued at approximately $541.9M, spread across 49 reported holdings.
During Q1 2024, Artia Global Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Eli Lilly & Co | Stock-Other | 17.98% | — | +187.50% | |
| 2 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 17.85% | — | -4.13% | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 14.48% | -7.04% | EXIT | |
| 4 | MRK | Merck & Co. Inc. | Stock-Healthcare | 10.06% | -0.01% | +15.19% | |
| 5 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 7.15% | +0.12% | +13.04% | |
| 6 | ABBV | Abbvie Inc | Stock-Healthcare | 3.32% | -0.63% | EXIT | |
| 7 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.92% | — | +405.04% | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.71% | +0.74% | — | |
| 9 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.60% | — | — | |
| 10 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.43% | — | — | |
| 11 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.41% | — | — | |
| 12 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.33% | — | +64.70% | |
| 13 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.26% | +0.89% | +178.78% | |
| 14 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.25% | — | — | |
| 15 | IRON | Disc Medicine Inc | Stock-Other | 1.09% | — | — | |
| 16 | PCVX | Vaxcyte Inc | Stock-Other | 1.05% | — | +97.78% | |
| 17 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.82% | -0.10% | EXIT | |
| 18 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.81% | — | — | |
| 19 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.72% | +0.04% | +10.77% | |
| 20 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.68% | — | — | |
| 21 | INSM | Insmed Inc | Stock-Healthcare | 0.64% | -18.15% | +57.78% | |
| 22 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.53% | — | — | |
| 23 | ASND | Ascendis Pharma A/S | Stock-Other | 0.48% | -0.81% | EXIT | |
| 24 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.46% | — | — | |
| 25 | ✓ | Merus N V | Stock-Other | 0.45% | — | — | |
| 26 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.42% | — | — | |
| 27 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 0.41% | — | — | |
| 28 | CRL | Charles River Laboratories | Stock-Healthcare | 0.38% | — | — | |
| 29 | JANX | Janux Therapeutics Inc | Stock-Other | 0.36% | — | — | |
| 30 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.35% | -0.46% | EXIT | |
| 31 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.35% | -0.04% | — | |
| 32 | ARVN | Arvinas Inc | Stock-Other | 0.33% | — | — | |
| 33 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 34 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.28% | — | — | |
| 35 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.26% | -0.08% | — | |
| 36 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.25% | — | +599.20% | |
| 37 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.23% | — | — | |
| 38 | EYPT | Eyepoint Inc | Stock-Other | 0.21% | +0.04% | +3.00% | |
| 39 | ANNX | Annexon Inc | Stock-Other | 0.21% | — | — | |
| 40 | VERA | Vera Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 41 | MGNX | Macrogenics Inc | Stock-Other | 0.19% | — | — | |
| 42 | KURA | Kura Oncology Inc | Stock-Other | 0.17% | — | — | |
| 43 | IMVT | Immunovant Inc | Stock-Other | 0.14% | — | — | |
| 44 | BMEA | Biomea Fusion Inc | Stock-Other | 0.11% | — | +39.29% | |
| 45 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 46 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.08% | — | — | |
| 47 | ✓ | Effector Therapeutics Inc | Stock-Other | 0.07% | — | — | |
| 48 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 0.06% | — | — | |
| 49 | 2JQ | Gritstone Bio Inc | Stock-Other | 0.05% | — | — |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 49 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ELI LILLY & CO, NVO, LLY) accounted for 62.0% of total reported equity market value during Q1 2024.
During Q1 2024, Artia Global Partners LP's top holdings by market value included ELI LILLY & CO (18.0%)、NVO (17.9%)、LLY (14.5%). The largest single position, ELI LILLY & CO, represented 18.0% of total portfolio value.
In Q1 2024, Artia Global Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.